UK/EU Bureau Chief @FierceBiotech
London, England
Joined October 2012
- Tweets10.2K
- Following1.9K
- Followers2.7K
- Likes4.2K
Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here...
fiercebiotech.com/biotech/jp…
For this week's @FierceBiotech podcast, I caught up with @novonordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer
fiercepharma.com/pharma/novo…
My dispatch from Day 1 of Jefferies 2024 - where everyone is now making the comparison with JPM (including the bad weather)
Jefferies London Healthcare Conference, which until last year had been a relatively cozy affair, has seemingly become a victim of its own success. Is the meeting the next JPM? fiercebiotech.com/biotech/so…
The KarXT crown looks secure in Bristol Myers' hands for a while at least
The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol Myers Squibb. $ABBV
fiercebiotech.com/biotech/ab…
While the in vivo program is taking center stage, @editasmed told me work on reni-cel is not being halted, with a “substantive clinical data set” lined up for #ASH24
Editas is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and signing a $238 million biobucks pact, while seeking a partner for its more advanced ex vivo sickle cell disease medicine. fiercebiotech.com/biotech/ed…
Today's news throws a spanner in two programs that CEO John Jacobs had been pointing to as potential growth drivers for the company fiercebiotech.com/biotech/fd…
At LSX in April, Gateway Labs' Julie Gilmore told me they planned to "go to geographies where we think we can make a difference.” Now it turns out one of those will be the UK...
fiercebiotech.com/biotech/li…
This morning sees another 2 biotechs joining the steady trickle of IPOs. Upstream has upsized its offering while CAMP4 has rebalanced its own $UBP $CAMP
fiercebiotech.com/biotech/up…
Sanofi's head of R&D told me the company will engage with the FDA “as soon as possible” to discuss filing for approval in non-relapsing secondary progressive MS
Sanofi’s tolebrutinib failed 2 out of 3 phase 3 MS trials that read out this morning, but the pharma is still planning an FDA filing fiercebiotech.com/biotech/sa…
Sanofi’s tolebrutinib failed 2 out of 3 phase 3 MS trials that read out this morning, but the pharma is still planning an FDA filing fiercebiotech.com/biotech/sa…
Looks like Bayer's Juergen Eckhardt was right when he told @fierce in June that he wouldn't let the company's restructuring affect their push for oncology innovation
fiercebiotech.com/biotech/ba…
James Waldron retweeted
.@FierceBiotech editor @GabrielleMasso9 was interviewed on the NYSE floor this morning! She shared insights on Fierce Biotech's Fierce 15 this year, the use of AI and other trends in the biotech market. Her segment starts at the 40:00 mark
Straight from the NYSE floor! Our editor @GabrielleMasso9 shares insights on this year's Fierce 15 and trends in the biotech market. youtube.com/live/R36O23Q92Dw… @NYSE
James Waldron retweeted
Our recently announced partnership with @GSK will develop a portfolio of entirely new medicines and vaccines to address unmet needs initially focused in respiratory and immunology. For more, read this @FierceBiotech piece by @JamesPharma: fiercebiotech.com/biotech/gs…
I noticed J&J had removed its Addex-partnered epilepsy drug from its pipeline. Turns out the Big Pharma had lost faith after April's phase 2 fail
fiercebiotech.com/biotech/jj…
What were the smartest deals in biopharma over the last few years? The @FierceBiotech team run down some of our favs👀
fiercebiotech.com/biotech/sm…
James Waldron retweeted
Great story here from @AGKootenay: "Despite releasing clinical data that included positive phase 3 results, receiving a fast-track designation from the FDA and receiving $10 million in non-dilutive funding, Vaxxinity’s shares still plummeted from the original list price."
Vaxxinity, which filed to delist from the Nasdaq last month, is choosing radical transparency about the “abusive relationship” that has defined the immunotherapy medicine company’s three-year stint as a public company. fiercebiotech.com/biotech/va…
James Waldron retweeted
We're growing the Fierce Biotech team! The first position we’re adding is a staff writer. We’re seeking someone with a few years of experience, ideally with a background in biotech writing. 🔗 recruiting.ultipro.com/QUE10…
Great interview by @AGKootenay and a reminder of how brutal the public markets can still be for biotechs
This Post is from an account that no longer exists. Learn more
BIG story from @maxonwifi about the latest in a series of major changes at Sanofi
BREAKING: Sanofi CSO Frank Nestle is leaving the company. fiercebiotech.com/biotech/sa…
More great reporting from @maxonwifi on the ongoing fallout from Bristol Myers' step back from cell therapy R&D
I should've known I was racing against @rleuty_biotech this morning, who got the jump on this story.
BMS is closing a Redwood City research site focused on cell therapy and I-O, consolidating the work at a Brisbane hub ~20 miles away.
fiercebiotech.com/biotech/bm…
